<DOC>
	<DOC>NCT00548093</DOC>
	<brief_summary>To assess the antitumor efficacy measured by the objective response rate of oral PF-00299804 taken daily, as single agent in patients with advanced NSCLC who failed at least one chemotherapy + erlotinib.</brief_summary>
	<brief_title>PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Advanced NonSmall Cell Lung Cancer (NSCLC) Prior treatment with and failure of at least one regimen of chemotherapy and erlotinib. Prior treatment with no more than two chemotherapy regimens, including adjuvant or combined modality treatment. Measurable disease . Eastern Cooperative Oncology Group (ECOG) Performance status 02 Tissue available for KRAS/ EGFR testing Creatinine clearance &gt; 40 cc/min or serum creat &lt; 1.5 x ULN Chemotherapy Radiotherapy Biological or investigational agents within 4 weeks of baseline disease assessment. Patients who lack of tolerance of erlotinib therapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>advanced</keyword>
	<keyword>previously treated</keyword>
</DOC>